Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of gpASIT+ in grass pollen-induced allergic rhinoconjunctivitis
2015-002105-11Phase 3Completed
- Sponsor
- TOOLS Life Science
- Start
- Jul 2015
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) and grass pollen allergy comparing gpASIT+ with Placebo (2 arms). Primary endpoint: Combined Symptom and Medication Score during peak grass pollen season. Started Jul 2015; status: completed.
02
Drugs
gpASIT+
03
Conditions
seasonal allergic rhinitis (SAR)grass pollen allergy
Beyond the preview
Go deeper on 2015-002105-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002105-11.